140 related articles for article (PubMed ID: 31449117)
1. New Drugs Treat Rare Heart Disease Caused by Transthyretin-Mediated Amyloidosis.
Aschenbrenner DS
Am J Nurs; 2019 Sep; 119(9):22-23. PubMed ID: 31449117
[No Abstract] [Full Text] [Related]
2. Tafamidis for the treatment of transthyretin amyloidosis.
Lorenzini M; Elliott PM
Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
[TBL] [Abstract][Full Text] [Related]
3. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
4. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
5. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
Kato TS; Ikeda N; Maurer MS; Ando Y; Tanno K
Circ J; 2019 Feb; 83(3):690. PubMed ID: 30185690
[No Abstract] [Full Text] [Related]
7. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Merkies IS
Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
[No Abstract] [Full Text] [Related]
8. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
9. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
10. Real-world versus trial patients with transthyretin amyloid cardiomyopathy.
Canepa M; Tini G; Musumeci B; Cappelli F; Milandri A; Mussinelli R; Autore C; Perfetto F; Rapezzi C; Perlini S
Eur J Heart Fail; 2019 Nov; 21(11):1479-1481. PubMed ID: 31339212
[No Abstract] [Full Text] [Related]
11. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
12. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
13. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
15. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
16. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.
Nawarskas JJ; Shephard EA
Cardiol Rev; 2020; 28(3):156-160. PubMed ID: 32101907
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
19. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
Castro J; Costa J; de Castro I; Conceição I
Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
[No Abstract] [Full Text] [Related]
20. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
